🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our latest study on the discovery and therapeutic targeting of cancer-associated cell surface RBPs is now published in Nature Biotechnology 🔥🔥 This exciting work that identified and characterised NPM1 as a glycoRNA-associated cell surface protein, was co-led by Ryan Flynn

Check out our latest study 👇🏻👇🏻🔥🔥

A breakthrough from our funded researcher Kostas Tzelepis and team! 💡 They've discovered a new target on AML cells - a protein called csNPM1 that’s normally hidden inside of cells, but appears on the surface of some cancer cells. 🔗 Read more: nature.com/articles/s4158…

An RNA-binding protein on leukemia cells provides an effective target for treatment in mouse models, according to a paper in Nature Biotechnology. go.nature.com/3YR25m7

Please join our colleagues Maria Eleftheriou & Eliza Yankova #AACR2025 to learn more about our lab’s collaborative work on the identification of novel epitrancriptomic therapies in the wider field of oncology. Join Maria on Monday afternoon in the Developmental Origins and

ICYMI 🔥

👇🏻👇🏻👇🏻👇🏻

👇🏻👇🏻🔥🔥

Check out the latest Nature Biotechnology Research Briefing regarding our recent work on therapeutic targeting of cell surface RBPs in cancer 🔥🔥 nature.com/articles/s4158…

We're incredibly proud to have backed this groundbreaking study by our funded researcher Kostas Tzelepis and team! It could pave the way for more precise, and less toxic, treatments for AML patients facing relapse. 👏 express.co.uk/news/uk/205335…

👇🏻👇🏻👇🏻

We're hiring! Join our team at Oxford to work on cutting-edge research in haematology and myeloproliferative neoplasms. Apply here 👉 my.corehr.com/pls/uoxrecruit… Learn more about our work 👉 imm.ox.ac.uk/research/resea… Ludwig Cancer MRC WIMM #AcademicJobs #Haematology #MPN #Oxford

Great news Storm Therapeutics!! Off we go🔥🔥 prnewswire.co.uk/news-releases/…

ASH is committing more than $12 million to address research funding challenges and support the next generation of hematologists. Learn more: ow.ly/sK3050W735W #Fight4Hematology

ASH has made an unprecedented investment of more than $12 million. Including ~$9 million increase in award funding. Total awards commitment of more than $20 million over the next 12 months....providing support for an additional 600+ awardees at all career stages. ASH

The Institute of Cancer Research is hiring a new Group Leader! A unique opportunity to establish your own research group at one of the UK’s leading cancer institutes. Competitive package, strong senior support, and access to world-class facilities. nature.com/naturecareers/…

From targeting a new marker in AML to uncovering the immune system’s role in MPNs and finding a gentler combo for childhood leukaemia - our funded researchers have been busy! 🧪👏 Here are just a few publication highlights 👉 leukaemiauk.org.uk/stories/resear…

2 weeks to go! Come and join us for this exciting half of day with a great lineup. Free to attend. No need to register. Looking forward to seeing you all!

5days until our London mini RNA symposium at Barts Cancer Institute (Queen Mary) on 16th July. We have put together excellent programme incl. talks by Kostas Tzelepis Magdalena Crossley Vikram Paralkar Hannah Lawson and early-career researchers. See you all next week . Programme 👇 thanks The RNA Society for support